NASDAQ:HGEN Humanigen (HGEN) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free HGEN Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume18,442 shsAverage Volume3.26 million shsMarket Capitalization$24,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Humanigen alerts: Email Address Ad DarwinYour Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)Click here to download your report About Humanigen Stock (NASDAQ:HGEN)Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Read More Ad DarwinYour Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)Click here to download your report HGEN Stock News HeadlinesMarch 24, 2024 | finance.yahoo.comHumanigen Inc (0KB2.BE)February 6, 2024 | morningstar.comHumanigen Inc HGENQApril 19, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…January 25, 2024 | markets.businessinsider.comLevi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action SettlementJanuary 17, 2024 | wsj.comFirm Retention Summary: HumanigenJanuary 5, 2024 | msn.comHumanigen Downfall: FDA Rejection For COVID-19 Drug Triggers Financial Crisis, BankruptcyJanuary 4, 2024 | news.yahoo.comCOVID-19 treatment developer Humanigen files for Chapter 11 bankruptcyJanuary 4, 2024 | wsj.comCovid-19 Treatment Developer Humanigen Files for BankruptcyApril 19, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…January 4, 2024 | msn.comCOVID pick Humanigen files for bankruptcyDecember 9, 2023 | finanznachrichten.deAktueller Chart HUMANIGEN AktieOctober 13, 2023 | uk.finance.yahoo.comHumanigen, Inc. (HGEN) stock historical prices & data – Yahoo FinanceAugust 11, 2023 | uk.finance.yahoo.comHumanigen, Inc. (HGEN) stock price, news, quote & history – Yahoo FinanceAugust 7, 2023 | finance.yahoo.comHumanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell TransplantationJuly 30, 2023 | proactiveinvestors.comHumanigen stock removed from S&P Total Market Index as firm faces...July 28, 2023 | proactiveinvestors.comHumanigen stock removed from S&P Total Market Index as firm faces bankruptcyJuly 25, 2023 | marketwatch.comHumanigen Shares Plunge 73% as Business Combination Fails, Going Concern Issues RaisedJuly 25, 2023 | markets.businessinsider.comWhy Is Humanigen (HGEN) Stock Down 72% Today?July 25, 2023 | msn.comHumanigen (NASDAQ:HGEN) Nosedives with Bankruptcy Looming LargeJuly 25, 2023 | seekingalpha.comHumanigen to weigh bankruptcy as shares delist from NasdaqApril 17, 2023 | nasdaq.comHumanigen (HGEN) Surges on Lenzilumab Study Data for LeukemiaApril 14, 2023 | finance.yahoo.comHumanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of LeukemiaDecember 20, 2022 | finance.yahoo.comHumanigen, Inc. (HGEN) Stock Historical Prices & Data - Yahoo FinanceNovember 14, 2022 | finance.yahoo.comHumanigen Reports Third Quarter 2022 Financial ResultsNovember 10, 2022 | finance.yahoo.comHumanigen Announces Participation and Presentation at Jefferies London Healthcare ConferenceOctober 31, 2022 | finance.yahoo.comHumanigen Announces Retention of SC&H Capital as Financial AdvisorOctober 19, 2022 | stockhouse.com2022-10-19 | NDAQ:HGEN | Press Release | Humanigen Inc. - StockhouseSee More Headlines Receive HGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:HGEN CUSIPN/A CIK1293310 Webwww.humanigen.com Phone650-243-3100FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.70 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.45) per share Price / BookN/AMiscellaneous Outstanding Shares119,080,000Free Float93,240,000Market Cap$24,000.00 OptionableNo Data Beta-1.04 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Cameron Durrant M.D. (Age 64)MBA, Chairman, CEO & Acting CFO Comp: $640kDr. Dale Chappell M.B.A. (Age 54)M.D., MBA, Chief Scientific Officer & Director Comp: $410kKey CompetitorsBruush Oral CareNASDAQ:BRSHNVN LiquidationNASDAQ:NOVNQAllied Healthcare ProductsNASDAQ:AHPIStatera BiopharmaNASDAQ:STABIgnyte AcquisitionNASDAQ:IGNYView All Competitors HGEN Stock Analysis - Frequently Asked Questions How were Humanigen's earnings last quarter? Humanigen, Inc. (NASDAQ:HGEN) announced its quarterly earnings results on Friday, November, 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.14. The business earned $1.04 million during the quarter, compared to the consensus estimate of $0.40 million. When did Humanigen's stock split? Humanigen shares reverse split on Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Humanigen? Shares of HGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HGEN) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humanigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.